We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Medifast's Metabolic Health Institute Strengthen Its Edge?
Read MoreHide Full Article
Key Takeaways
MED launches its Metabolic Health Institute, leveraging 45 years of scientific experience.
MED sees a $12 trillion metabolic health market and $16 trillion in prevention and optimization opportunities.
MED's Trilivy adds Refine and Renew phases to support metabolic flexibility and body composition.
Medifast, Inc. (MED - Free Report) is advancing its metabolic health strategy through the launch of its Metabolic Health Institute, proprietary science and an expanding product portfolio. During the third quarter of 2026, management positioned the Institute and its recent initiatives as important components of the company's transition from a traditional weight-loss business toward a comprehensive metabolic health platform. The initiative draws on more than 45 years of clinical and scientific experience and Medifast's proprietary metabolic synchronization science, which focuses on fat burning, preserving lean muscle and protecting metabolic health.
The Institute forms part of Medifast's research-oriented strategy, which management believes can deepen its differentiation in the expanding metabolic health market. Management cited market estimates presented at the McKinsey and Stanford Medicine Metabolic Health Business Building Summit 2026, which placed the existing metabolic health opportunity at $12 trillion, with another $16 trillion in largely untapped prevention and optimization opportunities. A Medifast survey of more than 1,000 U.S. adults conducted in September found that nearly 94% were concerned about at least one aspect of metabolic health, while 80% reported limited understanding of the subject.
Medifast is also advancing its Trilivy metabolic health system through three successive phases designed to help clients sustain progress and ultimately achieve optimal metabolic health. Following the foundational Reset phase, clients progress through Refine and Renew. Refine is designed to improve metabolic flexibility and body composition by promoting better fuel utilization, reducing fat storage and supporting greater muscle mass. Meanwhile, Renew focuses on optimizing metabolic health for long-term vitality. The system also equips coaches with additional tools to encourage long-term client engagement and support continued progress.
Overall, Medifast’s Metabolic Health Institute forms part of the company's broader effort to differentiate its offering through proprietary science, consumer education and a comprehensive metabolic health ecosystem.
The Zacks Rundown for MED
The Zacks Rank #3 (Hold) company's shares have gained 10.5% in the past three months against the industry’s decline of 1.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.53, lower than the industry’s average of 0.79.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal year bottom line calls for a year-over-year decline of 26.8%, whereas the same for next fiscal year earnings suggests 54.8% growth year over year.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks have been discussed below:
Lamb Weston Holdings, Inc. (LW - Free Report) engages in the production, distribution and marketing of frozen potato products in the United States, Canada, Mexico and internationally. LW currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Lamb Weston's current fiscal-year sales indicates a decline of 0.5%, and the same for earnings indicates growth of 7.6% from the prior-year levels. Lamb Weston delivered a trailing four-quarter earnings surprise of 22.1%, on average.
Ryohin Keikaku Co., Ltd. (RYKKY - Free Report) engages in the retail of household goods and food items in Japan and internationally. RYKKY currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for RYKKY's current fiscal-year sales implies growth of 3.9%, and the same for earnings implies a decline of 2.1% from the year-ago actuals.
The J. M. Smucker Company (SJM - Free Report) operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. SJM currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for SJM's current fiscal-year sales indicates a decline of 0.02%, and the same for earnings indicates growth of 17.1% from the prior-year levels. SJM delivered a trailing four-quarter earnings surprise of 13.8% on average.
View the Zacks #1 Rank List
Image: Shutterstock
Will Medifast's Metabolic Health Institute Strengthen Its Edge?
Key Takeaways
Medifast, Inc. (MED - Free Report) is advancing its metabolic health strategy through the launch of its Metabolic Health Institute, proprietary science and an expanding product portfolio. During the third quarter of 2026, management positioned the Institute and its recent initiatives as important components of the company's transition from a traditional weight-loss business toward a comprehensive metabolic health platform. The initiative draws on more than 45 years of clinical and scientific experience and Medifast's proprietary metabolic synchronization science, which focuses on fat burning, preserving lean muscle and protecting metabolic health.
The Institute forms part of Medifast's research-oriented strategy, which management believes can deepen its differentiation in the expanding metabolic health market. Management cited market estimates presented at the McKinsey and Stanford Medicine Metabolic Health Business Building Summit 2026, which placed the existing metabolic health opportunity at $12 trillion, with another $16 trillion in largely untapped prevention and optimization opportunities. A Medifast survey of more than 1,000 U.S. adults conducted in September found that nearly 94% were concerned about at least one aspect of metabolic health, while 80% reported limited understanding of the subject.
Medifast is also advancing its Trilivy metabolic health system through three successive phases designed to help clients sustain progress and ultimately achieve optimal metabolic health. Following the foundational Reset phase, clients progress through Refine and Renew. Refine is designed to improve metabolic flexibility and body composition by promoting better fuel utilization, reducing fat storage and supporting greater muscle mass. Meanwhile, Renew focuses on optimizing metabolic health for long-term vitality. The system also equips coaches with additional tools to encourage long-term client engagement and support continued progress.
Overall, Medifast’s Metabolic Health Institute forms part of the company's broader effort to differentiate its offering through proprietary science, consumer education and a comprehensive metabolic health ecosystem.
The Zacks Rundown for MED
The Zacks Rank #3 (Hold) company's shares have gained 10.5% in the past three months against the industry’s decline of 1.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.53, lower than the industry’s average of 0.79.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current fiscal year bottom line calls for a year-over-year decline of 26.8%, whereas the same for next fiscal year earnings suggests 54.8% growth year over year.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks have been discussed below:
Lamb Weston Holdings, Inc. (LW - Free Report) engages in the production, distribution and marketing of frozen potato products in the United States, Canada, Mexico and internationally. LW currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Lamb Weston's current fiscal-year sales indicates a decline of 0.5%, and the same for earnings indicates growth of 7.6% from the prior-year levels. Lamb Weston delivered a trailing four-quarter earnings surprise of 22.1%, on average.
Ryohin Keikaku Co., Ltd. (RYKKY - Free Report) engages in the retail of household goods and food items in Japan and internationally. RYKKY currently carries a Zacks Rank #2 (Buy).
The Zacks Consensus Estimate for RYKKY's current fiscal-year sales implies growth of 3.9%, and the same for earnings implies a decline of 2.1% from the year-ago actuals.
The J. M. Smucker Company (SJM - Free Report) operates as a health and wellness company that provides habit-based and coach-guided lifestyle solutions to address obesity and support a healthy life in the United States. SJM currently carries a Zacks Rank of 2.
The Zacks Consensus Estimate for SJM's current fiscal-year sales indicates a decline of 0.02%, and the same for earnings indicates growth of 17.1% from the prior-year levels. SJM delivered a trailing four-quarter earnings surprise of 13.8% on average.